FILGRASTIM
AML With Mutated NPM1
Kura Oncology, Inc.protein_peptidePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
9 Active assets in the AML With Mutated NPM1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Shen yang | Phase 3 | B |
Daunorubicin Shen yang | Phase 2 | B |
Venetoclax Kura Oncology, Inc. | Phase 2 | B |
Gilteritinib Kura Oncology, Inc. | Phase 1 | CC |
Idarubicine Kura Oncology, Inc. | Phase 1 | CC |
View all 9 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →